Viral Vector and Plasmid DNA Manufacturing Market to grow with a CAGR of 10.85% through 2030

Growing Investment in Biopharmaceutical R&D and Increasing Prevalence of Chronic and Genetic Diseases are expected to drive the Global Viral Vector and Plasmid DNA Manufacturing Market growth in the forecast period, 2026-2030

According to TechSci Research report, “Viral Vector and Plasmid DNA Manufacturing Market – Global Industry Size, Share, Trends, Competition Forecast & Opportunities, 2030F”, the Global Viral Vector and Plasmid DNA Manufacturing Market stood at USD 6.80 Billion in 2024 and is anticipated to grow with a CAGR of 10.85% in the forecast period, 2026-2030.

As an increasing number of gene therapies progress through clinical pipelines and receive regulatory approvals, the demand for high-purity, GMP-grade viral vectors and plasmid DNA is escalating sharply. Companies specializing in vector and plasmid manufacturing are well-positioned to capitalize on this momentum. The growing adoption of vectors such as AAV, lentivirus, and retrovirus in gene therapy trials underscores a sustained and diversified need for manufacturing capacity across multiple platforms. The continued growth of global gene therapy trials has created a significant uptick in GMP manufacturing requirements, particularly in early-phase and late-stage clinical development. CDMOs that can deliver scalable, regulatory-compliant, and cost-efficient production solutions are gaining strategic traction. The ability to flex capacity and maintain high standards of quality is increasingly seen as a competitive differentiator in a crowded marketplace.

Global regulatory bodies including the FDA and EMA have established accelerated approval mechanisms, such as the RMAT designation, to streamline the development of regenerative and gene-based therapies. These expedited pathways lower regulatory risk and reduce time-to-market, encouraging biopharma companies to invest in viral vector-based platforms. In turn, manufacturers with upstream capabilities benefit from heightened demand and faster project onboarding. The shift toward precision and personalized therapies which often require custom-engineered vectors has created demand for agile, small-batch, and highly tailored manufacturing models. CDMOs that offer modular, or on-demand vector production are particularly well-suited to support the needs of personalized treatment programs, where production timelines and quality consistency are critical.

Innovations in bioprocessing such as single-use systems, continuous processing, and automated production platforms are enhancing both the scalability and efficiency of viral vector and plasmid DNA manufacturing. Early adopters of these advanced technologies can offer shorter turnaround times, superior quality assurance, and competitive pricing, giving them a clear advantage in securing long-term manufacturing partnerships. Biotech companies are increasingly outsourcing vector and plasmid manufacturing to specialized CDMOs, allowing them to focus internal resources on clinical development and product innovation. Full-service CDMOs offering integrated solutions across R&D, process development, analytical support, and GMP production are emerging as preferred partners. These organizations are critical enablers of accelerated program timelines and de-risked supply chains in the gene therapy ecosystem.

Browse over XX market data Figures spread through XX Pages and an in-depth TOC on "Global Viral Vector and Plasmid DNA Manufacturing Market”

The Global Viral Vector and Plasmid DNA Manufacturing Market is segmented into product type, application, regional distribution, and company.

Based on its application, the Cancer segment dominated the Global Viral Vector and Plasmid DNA Manufacturing Market. Cancer remains a leading cause of mortality worldwide, and there is a substantial unmet medical need for more effective treatments. Gene therapy, including the use of viral vectors and plasmid DNA, holds promise as a novel approach to targeting and treating various types of cancer. Ongoing research in oncology has led to a deeper understanding of the genetic and molecular basis of cancer. This knowledge has paved the way for the development of gene therapies that can target specific genetic mutations and pathways responsible for cancer growth. Gene therapies can be designed to target cancer cells specifically, minimizing damage to healthy tissues and reducing side effects compared to traditional chemotherapy and radiation therapy. This targeted approach is particularly attractive for treating cancer.

Based on region, Asia-pacific region to fastest growth in the Global Viral Vector and Plasmid DNA Manufacturing Market. Many countries in the Asia-Pacific region have been increasing their investments in biotechnology and life sciences. Governments and private investors have recognized the potential of gene therapy, vaccine development, and other biotechnology applications, leading to significant funding for research and development. APAC countries, including China, South Korea, India, and Japan, have witnessed substantial growth in their pharmaceutical and biotechnology industries. These industries play a pivotal role in driving the demand for viral vectors and plasmid DNA for gene therapy and biomanufacturing applications. The region has a growing pool of skilled scientists, researchers, and biopharmaceutical professionals who are contributing to the development and manufacturing of viral vectors and plasmid DNA.

Major companies operating in Global Viral Vector and Plasmid DNA Manufacturing Market are:

• Oxford Biomedica PLC
• Cognate BioServices Inc.
• Cell and Gene Therapy Catapult Ltd.
• FinVector Vision Therapies
• Fujifilm Holdings Corporation (Fujifilm Diosynth Biotechnologies)
• SIRION Biotech GmbH
• Merck KGaA
• Thermo Fisher Scientific Inc.
• Uniqure NV
• Catalent Inc.

Download Free Sample Report

Customers can also request for 10% free customization on this report.

“The Global Viral Vector and Plasmid DNA Manufacturing Market is undergoing a period of accelerated growth, driven by the expanding gene and cell therapy pipeline, rising demand for personalized medicine, and a supportive regulatory environment. As biopharmaceutical innovation continues to evolve, the need for high-quality, scalable, and compliant manufacturing solutions is becoming more critical than ever. Companies that invest in advanced technologies, flexible production platforms, and end-to-end capabilities are well-positioned to capture long-term value and establish themselves as key enablers in the future of genetic medicine.,” said Mr. Karan Chechi, Research Director of TechSci Research, a research-based management consulting firm.

“Viral Vector and Plasmid DNA Manufacturing Market – Global Industry Size, Share, Trends, Opportunity & Forecast, Segmented by Product Type (Plasmid DNA, Viral Vector, Non-viral Vector), Application (Cancer, Genetic Disorder, Infectious Disease, Others), By Region, & Competition, 2020-2030F”, has evaluated the future growth potential of Global Viral Vector and Plasmid DNA Manufacturing Market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in Global Viral Vector and Plasmid DNA Manufacturing Market.

Contact

TechSci Research LLC

420 Lexington Avenue, Suite 300,

New York, United States- 10170

Tel: +1-332-258-6602

Email: sales@techsciresearch.com